AUTHORS
Katherine J. Feder, MD, MS, Neville Lee Jr, BSc, BA2, Jessica Freydman, PharmD3, Katie Erdos, BA4, David Sirignano5, Chi-Joan How, MD6, Michelle Hyunju Lee, MD7, Daniel J DeAngelo, MD, PhD8, Jean M. Connors, MD9, Richard Stone, MD10, Marlise Rachael Luskin, MD, MSCE11, Joseph Scandura, MD, PhD12, Ghaith Abu-Zeinah I, MD13, Gabriela Soriano Hobbs, MD14
AFFILIATIONS
1 Dana Farber Cancer Institute, Boston, United States, Mass General Brigham Cancer Institute, Boston, United States
2 Weill Cornell Medicine, New York, United States
3 Massachusetts General Hospital, Boston, United States
4 Weill Cornell Medicine, New York, United States
5 Massachusetts General Hospital, Boston, United States
6 Brigham and Women's Hospital, Boston, United States
7 Massachusetts General Hospital, Boston, United States
8 Dana Farber Cancer Institute, Boston, United States
9 Dana Farber Cancer Institute, Boston, United States
10 Dana Farber Cancer Institute, Boston, United States
11 Dana Farber Cancer Institute, Boston, United States
12 Weill Cornell Medicine, New York, United States
13 Weill Cornell Medicine, New York, United States
14 Massachusetts General Hospital, Boston, United States
ABSTRACT
Introduction: In the United States, the annual prevalence of major depressive disorder and anxiety disorders is ~7–10% and ~13%, respectively. Rates are higher among patients with myeloproliferative neoplasms (MPNs), with depression affecting ~12–25% and anxiety ~21–31%. The 2021 FDA approval of ropeginterferon alfa-2b (ropeg) for polycythemia vera (PV) renewed interest in interferons by adding a first line therapy with disease-modifying potential. Ropeg is also being investigated for essential thrombocythemia (ET) and myelofibrosis (MF). However, concerns about interferon-associated neuropsychiatric toxicity excluded patients with depression and/or anxiety (depression/anxiety) from pivotal trials. Tolerance of ropeg is unknown in MPN patients with baseline depression/anxiety; this real-world analysis was designed to evaluate this gap in knowledge.
Methods: Patients prescribed ropeg from Mass General Brigham (MGB) specialty pharmacy from 1/2022-6/2025 were identified; patients treated with ropeg at Weill Cornell Medicine (WCM) with depression/anxiety from 11/2021-7/2026 were identified from the WCM MPN Research Data Repository. Data was collected via manual chart abstraction. Baseline depression/anxiety was defined as documented depression/anxiety before ropeg initiation; remission status was determined from clinician notes. MGB patients without either condition were included as a site-specific descriptive comparator.
Results: Across cohorts, 43 patients had baseline depression/anxiety (22 MGB, 21 WCM); the MGB dataset contained 63 with neither condition. Diagnoses often overlapped; 21 had depression and 39 anxiety. 35 (81%) had PV and 8 (19%) ET. Median age at ropeg start was 52 years (range 20–70); 27 (63%) were female. 40 (93%) were White. All but 2 had a JAK2 V617F mutation.
Of the 43 patients with depression/anxiety, 16 (37%) had high risk disease (age≥60 or prior thrombosis). Median starting ropeg dose was 100mcg every 2 weeks (q2w) (range 50–200). Median final dose, standardized to q2w, was 200mcg q2w (range 25–500). Median duration of ropeg therapy was 14.5 months (range 1–34); 27 (63%) patients remained on treatment at the time of data collection.
At ropeg initiation, 30 (70%) patients were on medication for depression/anxiety and 21 (49%) were under the care of a mental health specialist, 18 (42%) patients’ depression/anxiety was in remission, 18 (42%) in partial remission, 5 (12%) not in remission, and 2 (5%) unknown. During treatment, 13 (30%) patients escalated their medications.
16 (37%) patients discontinued ropeg: 1 (6%) for lack of response, 1 (6%) for progression to MF, and 14 (88%) for adverse events (AEs). Of the 14 who discontinued for AEs, 6 (43%) discontinued for worsening depression/anxiety. Of these 6, their depression/anxiety at ropeg start was in remission (n=3), partial remission (n=2), and not in remission (n=1). Depression/anxiety resolved after discontinuation in 5 of the 6 affected patients; depression persisted in 1 patient with a significant history.
In the MGB cohort, 63 patients without baseline depression/anxiety were treated for a median duration of 16 months (range 1–42); none developed depression/anxiety on therapy. 15 (24%) of these patients discontinued ropeg: 1 (7%) for disease progression and 14 (93%) for AEs.
Non-psychiatric AE-related discontinuation in the depression/anxiety cohort vs comparator cohort was 23% vs 22%; discontinuation for worsening depression/anxiety was 14% vs 0%, respectively.
Conclusion: This is the first longitudinal analysis of ropeg in MPN patients with baseline depression/anxiety. In this retrospective multicenter cohort, a substantial proportion of patients initiating ropeg had baseline depression/anxiety consistent with the elevated prevalence in MPN patients. While non-psychiatric AE-related discontinuations were comparable, discontinuation due to worsening depression/anxiety was solely in the cohort with baseline diagnoses. Half of these discontinuations were in patients with depression/anxiety not in remission at ropeg initiation. All but one resolved with drug discontinuation. The relationship between status of depression/anxiety at ropeg start and drug tolerance warrants further investigation. Our data suggest baseline depression/anxiety should not automatically preclude ropeg interferon use. Larger prospective studies are needed; patient selection, proactive counseling, and longitudinal monitoring remain essential.
DISCLOSURES
Katherine J. Feder, MD, MS: Sobi - Consultancy (Includes expert testimony)